Shrinidhi Nathany/LinkedIn
Dec 16, 2025, 23:14
Shrinidhi Nathany: MRD in AML – From a Test to a Treatment Decision
Shrinidhi Nathany, Consultant Molecular Hematology and Oncology at Fortis Memorial, posted on LinkedIn:
“MRD in AML: From a Test to a Treatment Decision (ELN-DAVID 2025 Update)
Measurable residual disease (MRD) has firmly moved beyond being a laboratory metric.
The 2025 ELN-DAVID consensus update positions MRD as a central clinical decision-making tool in acute myeloid leukemia.
What’s new and practice-changing?
- MRD interpretation is now genetics-specific, aligned with ELN 2022 risk groups
- Introduction of low-level MRD (MRD-LL) and qualitative MRD response categories – Optimal, Warning, High-risk
- Clear linkage of MRD results to clinical action, not just prognosis
- Ultra-high-sensitivity NGS (≤0.01%) now recommended for FLT3-ITD MRD, especially pre-transplant
- Refined, lower thresholds for NPM1 MRD, with clear PB vs BM distinctions
- Explicit caution against misinterpreting CHIP-associated mutations as MRD
Why this matters
- MRD is no longer binary. The same MRD level can mean very different things depending on:
genetics, assay, tissue, and timing. - This framework finally brings context and clarity to MRD-guided decisions.
For clinicians, pathologists, and transplant teams, this update is a must-read and should rapidly translate into:
standardized reporting, multidisciplinary discussion, and more precise patient care.”
Stay informed with Hemostasis Today.
-
Sep 24, 2026, 06:08Christopher Salerno: AI-Powered At-Home Anemia Screening Advances Telehealth Access
-
Sep 24, 2026, 05:38Aya Qattan: When a Normal CBC Does Not Mean Normal Iron Status
-
Sep 24, 2026, 05:11Mastering Warm Autoimmune Hemolytic Anemia Diagnosis and Practice – ASH Education
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation
-
Sep 23, 2026, 13:58The New B12 Diagnostic Algorithm: From Serum Cobalamin to Functional Deficiency
-
Sep 23, 2026, 13:56Noha Soror: Preparing for Hematology and Medical Oncology Board Certification
-
Sep 23, 2026, 13:46Ugochi Ogu: What Can Platelet Proteomics Reveal about Pain and Neurocognitive Vulnerability in Sickle Cell Disease?